 cyclophosphamid ifosfamid combin neoadjuv chemotherapi advanc nonsmall-cel lung cancer meta-analyt review twenty-thre patient resect unresect non-small-cel lung cancer stage iiia iiib neoadjuv chemotherapi patient cycl preoper chemotherapi agent i.v drug hematuria six patient partial respons patient underw thoracotomi macroscop residu diseas mean time progress whole group month fifteen patient progress diseas local metastas distant metastas chemotherapi cycl cyclophosphamide-ifosfamid dose patient hospit fever neutropenia nadir two-alkyl non-cisplatin regimen cisplatin-bas regimen ineffect trial